Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

MT Newswires Live

昨天

Verastem's (VSTM) shares are not fully valuing its growth potential, considering a "major upcoming catalyst" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.

Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.

RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.

Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.

RBC has an outperform speculative risk rating on the stock and a $14 price target.

Price: 7.65, Change: +0.10, Percent Change: +1.32

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2668092484"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668092484\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668092484?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668092484","market":"hk","top_or_hot":-1,"title":"Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.</p><p>RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.</p><p>Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.</p><p>RBC has an outperform speculative risk rating on the stock and a $14 price target.</p><p>Price: 7.65, Change: +0.10, Percent Change: +1.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem's Shares Not Fully Valuing its Growth Potential, RBC Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-18 22:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.</p><p>RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.</p><p>Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.</p><p>RBC has an outperform speculative risk rating on the stock and a $14 price target.</p><p>Price: 7.65, Change: +0.10, Percent Change: +1.32</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668092484","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668092484","pubTimestamp":1789743079,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verastem's  shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.RBC has an outperform speculative risk rating on the stock and a $14 price target.Price: 7.65, Change: +0.10, Percent Change: +1.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"加拿大皇家银行表示，Verastem 的股票并未充分发挥其增长潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5},"content_text":"Verastem's (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.RBC has an outperform speculative risk rating on the stock and a $14 price target.Price: 7.65, Change: +0.10, Percent Change: +1.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}